Quick Facts

• Respiratory Infections: Helps manage conditions like bronchitis, pneumonia, and acute bacterial exacerbations of chronic bronchitis.
• Ear, Nose, and Throat: Used for bacterial infections, including acute otitis media (ear infection), pharyngitis, and tonsillitis.
• Skin and Soft Tissue: An option for treating specific bacterial infections of the skin and related structures.
• Urinary Tract: Supports the management of certain urinary tract infections.
• Other Uses: May be used to address Lyme disease in its early stage and uncomplicated gonorrhea.

---

Xorimax is a prescription medication utilized to address a variety of bacterial infections caused by susceptible microorganisms. The therapeutic application of this agent focuses on supporting the resolution of infection across multiple systems in the body. It is frequently considered for managing lower respiratory tract infections, which include certain types of pneumonia and bronchitis. The medication also plays a role in the treatment of ear, nose, and throat infections, such as otitis media and tonsillitis.

Additional uses include the therapeutic management of bacterial infections affecting the urinary tract and the skin and soft tissues. Furthermore, it is indicated for the treatment of uncomplicated gonorrhea and is an established option for addressing early-stage Lyme disease. Patients should always consult a licensed healthcare professional for a precise diagnosis and personalized treatment plan, based on approved product labeling.

Contraindications and Allergies

Xorimax is strictly contraindicated for any individual with a known hypersensitivity to the active ingredient, Cefuroxime, or to any antibiotic belonging to the cephalosporin class. Use is also prohibited if there is a history of severe allergic reaction to any other beta-lactam antibiotic, such as penicillin, due to cross-sensitivity risk.

---

Age-Based Eligibility

The medicine is approved for adults and adolescents aged 13 years and older. For pediatric patients between 3 months and 12 years, the drug is typically administered as an oral suspension, as the tablet form is restricted for children who cannot swallow pills whole. Safety and effectiveness have not been established for infants under 3 months of age, and older adults typically do not require dose adjustment solely based on age.

---

Conditional Use and Restrictions

Specific conditions define conditional eligibility. Patients with reduced kidney function require special consideration because the drug's elimination is prolonged. The oral suspension form is restricted for individuals with Phenylketonuria (PKU) due to the formulation containing phenylalanine. Use during pregnancy and lactation is classified as conditional, as the drug is known to be excreted in human milk.

Interactions with other medicines and products

This section describes officially documented interaction patterns for Cefuroxime based on regulatory information.

Category	Interacting Substance/Product	Official Outcome or Restriction
Pharmacokinetic (Renal)	Probenecid	Co-administration is not recommended as it increases the systemic exposure of Cefuroxime by reducing its renal clearance.
Pharmacokinetic (Absorption)	Gastric Acidity Reducers (e.g., Antacids, H2-receptor antagonists, PPIs)	Lower the bioavailability (absorption) of Cefuroxime Axetil. Administration of antacids should be separated by at least 2 hours.
Drug–Food	Food (Meals)	Increases the oral absorption and bioavailability of Cefuroxime Axetil.
Pharmacodynamic	Oral Contraceptives	Potential for reduced efficacy due to effects on gut flora that may lower oestrogen reabsorption.
Lab Test Interference	Copper Reduction Tests (for urine glucose)	May cause a false-positive result.
Lab Test Interference	Ferricyanide Tests (for blood/plasma glucose)	May cause a false-negative result.

---

The regulatory profile highlights that the oral absorption of Cefuroxime Axetil is dependent on gastric acidity, which is why acid-reducing agents decrease the drug's exposure. Conversely, absorption is enhanced by food. Probenecid co-administration is officially restricted because it interferes with the drug's renal elimination, leading to significantly higher plasma concentrations. Furthermore, the official labeling notes the potential for reduced efficacy of oral contraceptives and alerts for interference with specific glucose laboratory assays.

Cefuroxime, the active compound in Xorimax, achieves its mechanism of action by targeting essential bacterial enzymes known as Penicillin-binding proteins (PBPs). These proteins, situated on the bacterial inner membrane, are crucial transpeptidases required for the final cross-linking of the cell wall's peptidoglycan layer. Cefuroxime acts as an irreversible inhibitor by forming a stable covalent bond with the PBP active site.

This molecular blockade initiates a lethal mechanistic cascade: the resulting defective cell wall structure cannot withstand the high internal osmotic pressure of the cell. This physiological imbalance leads directly to cellular lysis (rupture) and death, defining the core bactericidal effect that results in the reduction of the susceptible pathogen population. Furthermore, Cefuroxime exhibits structural stability against hydrolysis by many common beta-lactamase enzymes. By resisting this enzymatic defense, the drug is protected, preserving its functional interaction with the bacterial targets.

Administration Routes and Forms

Xorimax is administered via two primary pathways corresponding to its distinct chemical forms: Cefuroxime Axetil is used for the oral route (tablets and suspension), and Cefuroxime Sodium is used for the parenteral (Intravenous or Intramuscular) route. The oral form is available as 250 mg and 500 mg tablets, while the injectable form is supplied in 750 mg and 1.5 g vials.

---

Standard Regimens and Duration

For most common bacterial infections, the oral regimen is typically 250 mg or 500 mg taken every 12 hours. Parenteral use for systemic infections usually involves 750 mg or 1.5 g doses administered every 8 hours. The entire course of treatment often lasts 7 to 10 days, although the duration is specifically extended to 20 days for conditions like early Lyme disease. Surgical prophylaxis protocols utilize a single 1.5 g IV dose during the induction of anesthesia.

---

Administration Conditions and Adjustments

The oral suspension must be reconstituted and taken with food to ensure proper absorption. Tablets should be swallowed whole and cannot be substituted for the oral suspension on a milligram-per-milligram basis due to differences in absorption. Dosage adjustments are mandatory for patients with documented renal impairment, particularly when using the parenteral route, to manage clearance of the drug. For example, patients with CrCl 10 to 20 mL/min typically receive 750 mg every 12 hours. Furthermore, injectable administration is restricted to a maximum of 750 mg per single intramuscular injection site.

Research Evidence: Active Ingredient Cefuroxime Axetil

Research has examined the active ingredient Cefuroxime axetil for its role in managing various bacterial infections. This compound is a second-generation cephalosporin antibiotic.

Efficacy Studies

• Target Infections: Clinical trials have focused on the compound's use in susceptible infections of the lower respiratory tract (e.g., bronchitis, pneumonia), otitis media (ear infection), urinary tract, skin and soft tissues, and early Lyme disease. These studies typically measure the microbiological cure rate and clinical resolution of symptoms.
• Outcome Measures: Studies found that the compound was associated with favorable outcomes in clearing the target bacteria and reducing infection-related symptoms, such as fever and pain, in the studied populations. Findings across different indications, however, show variations in reported outcomes based on the type and severity of the infection.

Limitations and Scope

Despite a history of use, the evidence base carries limitations that restrict broad conclusions about its profile and suitability:

• Study Duration: Most trials assessed the treatment over short, defined courses (typically 5 to 10 days) necessary to resolve the acute infection. The effect and safety profile beyond this acute treatment period have not been established by the currently available research.
• Population Focus: Studies have evaluated the compound's use in non-elderly patients with specific, uncomplicated bacterial infections. Research has not been conclusive on its use in populations with pre-existing conditions like severe liver or kidney dysfunction, where caution is generally advised.

Comparative Findings

Early research has compared the compound's outcomes against both placebo and other antibiotics. While some studies reported a greater difference compared to placebo in achieving clinical cure, direct head-to-head comparisons with all other currently used first-line therapies are limited, often focusing on narrow subsets of bacterial pathogens.

Key Studies & References Cefuroxime - StatPearls (Review of FDA Approved Indications and Uses)

Common questions about Xorimax (FAQ)

---

Q: How does Xorimax differ from first-generation cephalosporin antibiotics?

Xorimax (Cefuroxime) is classified in official documents as a second-generation cephalosporin antibiotic. This regulatory classification is associated with enhanced stability against certain bacterial defense mechanisms, such as beta-lactamase enzymes. It also typically provides a broader range of activity against different types of susceptible bacteria compared to first-generation agents.

---

Q: Is Xorimax effective against viral infections, such as the common cold or flu?

No. Xorimax is a beta-lactam antibacterial agent (antibiotic). Regulatory information indicates it is only authorized for treating infections proven or strongly suspected to be caused by susceptible bacteria. It does not work against viral illnesses like the common cold or influenza.

---

Q: How long does Xorimax generally stay in the body after the last dose is taken?

Official pharmacological data show that the elimination half-life of Cefuroxime in adults with normal kidney function is typically around one to two hours. The drug is primarily cleared from the body by the kidneys, and regulatory information notes this is the basis for dosage adjustments in patients with reduced kidney function.

---

Q: Why is it important for patients to finish the entire prescribed course of Xorimax?

Regulatory warnings emphasize the need to complete the full treatment course to support the reduction of drug-resistant bacteria. Stopping treatment early, even when symptoms improve, may increase this risk. The completion of the course supports the elimination of susceptible bacteria from the infection site.

---

Q: Is it common for patients to experience a bitter taste when taking Xorimax?

Yes, official product information and clinical documentation report that an unusual or unpleasant taste in the mouth or a change in taste is a possible side effect. The tablet formulation specifically is noted to have a strong, persistent bitter taste if it is not swallowed whole, but is crushed or chewed.

---

Q: What is the standard procedure if a patient forgets to take a dose of Xorimax?

Regulatory patient counseling information states that if a dose is missed, the recommended practice is to omit the missed dose and take the next dose at the regular scheduled time. Patients are cautioned not to take a double dose to make up for the omitted one.

---

Q: Is it safe to consume alcohol while a patient is taking Xorimax?

Official regulatory documentation for Cefuroxime (Xorimax) does not list a specific, formal interaction warning regarding the consumption of alcohol. This means there is no noted disulfiram-like effect. Official information suggests consulting a healthcare professional for guidance on alcohol use with any medication.

---

Q: What is the general information about taking Xorimax with common pain relievers like ibuprofen?

Official regulatory documents, which list clinically significant drug interactions, do not identify specific interactions between Cefuroxime (Xorimax) and common over-the-counter pain relievers such as Ibuprofen (an NSAID) or Paracetamol/Acetaminophen.

---

Q: Is Xorimax generally studied for use during pregnancy, according to regulatory information?

Regulatory agencies have often categorized Xorimax based on available data, noting that animal studies show no evidence of fetal harm. While human data are limited, current information has not shown an increased risk of congenital defects. Use during pregnancy is classified as conditional, indicating the decision involves specialized consideration by a healthcare provider.

---

Q: Does Xorimax affect patients who have a history of liver problems?

Regulatory documents indicate that patients with hepatic impairment (liver problems) may be at risk for a fall in prothrombin activity, which is a blood-clotting factor. Regulatory documentation notes that monitoring of liver function is a factor to consider in this context, and transient elevations in liver enzymes have been reported as common adverse reactions.

---

Q: Are there special precautions for elderly patients when using Xorimax?

Regulatory guidelines indicate that while dose adjustments are typically not necessary for older patients based on age alone, special consideration is given because they are more likely to have decreased renal function. This may necessitate a dosage adjustment if kidney impairment is present.

---

Q: Is Xorimax considered a drug that has habit-forming potential?

No. Official regulatory classifications confirm Xorimax (Cefuroxime) is a beta-lactam antibiotic. It is not scheduled by controlled substance agencies and has no known risk for habit-forming or addictive potential.

---

Q: What is the Jarisch-Herxheimer reaction, and is it a possible reaction when using Xorimax for certain infections?

The Jarisch-Herxheimer reaction is listed in regulatory documentation as a possible adverse reaction. It is an acute response that can occur when treating certain infections caused by spirochetes, such as Lyme disease, with Xorimax. It typically involves symptoms like fever, chills, or headache as the bacteria are rapidly killed.

---

Q: How long after finishing the course of Xorimax might gastrointestinal side effects potentially continue?

While common side effects like diarrhea typically resolve quickly after stopping the medicine, regulatory warnings note a risk for severe diarrhea related to Clostridioides difficile (CDAD). This condition has been reported to occur up to two months or more after the antibiotic treatment has finished.

---

Q: Are there any reported instances of Xorimax causing muscle aches or joint pain?

Review of the full adverse reactions profile indicates that symptoms such as joint or muscle pain have been noted in broader post-marketing surveillance reports for the drug class. However, these are not typically listed among the common or uncommon expected side effects.

---

Q: What information exists about Xorimax’s effectiveness against Staphylococcus aureus infections?

Official microbiology information indicates that Xorimax is considered effective only against methicillin-sensitive strains of Staphylococcus aureus. It is generally not effective against the more resistant strains, specifically Methicillin-Resistant Staphylococcus aureus (MRSA).

How to Store and Dispose of Xorimax (Cefuroxime Axetil)

Storage and disposal requirements for Xorimax must strictly follow official regulatory guidelines to maintain product stability and ensure safety.

Storage Requirements

• Tablets/Dry Granules: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The product must be protected from excessive moisture and kept in its original, securely closed container.
• Reconstituted Oral Suspension: The liquid suspension requires refrigeration (2 C to 8 C or 36 F to 46 F) and must not be frozen. The suspension must be discarded after 10 days of storage.
• Child Safety: All forms of Xorimax must be kept out of the reach and sight of children.

Disposal Instructions

Expired or unused Xorimax should be managed through an official drug take-back program or authorized collection site. If such a program is not available, the medication should be mixed with an undesirable substance (e.g., dirt, coffee grounds) and placed in a sealed container for household trash disposal. Xorimax must not be flushed down the toilet or sink.